Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

Zhiyan Consulting Data Center released the net profit ranking of Chinese medical device listed companies in the first quarter of 2022, ranking 109 Chinese listed medical companies according to their net profit in the first quarter of 2022.

Color Health said on Friday that it has partnered with the US Centers for Disease Control and Prevention to increase access to no-cost, PCR-based, COVID-19 testing.

Quest Diagnostics said Thursday that it is participating in the Centers for Disease Control and Prevention's (CDC) Increasing Community Access to Testing (ICATT) for COVID-19 program.

How did Chinese listed companies perform in the first half of the year? As of June 30, 2022, a total of 8,392 Chinese listed companies have been listed on 16 major exchanges in the world, including Shanghai, Shenzhen, Beijing, Hong Kong and New York.

Meridian Bioscience announced on Thursday that it has entered into an agreement to be acquired by a newly formed affiliate of Korean diagnostic company SD Biosensor and investment firm SJL Partners for about $1.53 billion.

MirXes, a Singapore-based RNA testing firm, said on Thursday it has signed a memorandum of understanding with several Singapore universities and hospitals to launch a study of circulating microRNA and DNA methylation biomarkers for multi-cancer early detection.

Recently, Peng Yang, Vice President of Danaher Global Yang Peng visited Suzhou BioLihe. The two parties had an in-depth communication on the Danaher Business System (DBS) and BioLihe’s production and operation.

Guardant Health and Chinese clinical laboratory firm Adicon said on Wednesday that they have signed a strategic partnership under which Adicon has licensed Guardant's tissue and blood-based genomic cancer assays

BioMérieux, Boehringer Ingelheim, and Evotec announced on Wednesday the creation of a joint venture to develop and commercialize new antimicrobials and diagnostics.

Bio-Techne said on Wednesday that it has recently received CE marking and launched in Europe its assay for human papillomavirus for use in patients with head and neck cancer.